MoonLake Immunotherapeutics
General ticker "MLTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B
MoonLake Immunotherapeutics follows the US Stock Market performance with the rate: 6.5%.
Estimated limits based on current volatility of 3.1%: low 51.03$, high 54.30$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [28.36$, 65.55$]
- 2024-12-30 to 2025-12-30 estimated range: [16.43$, 42.16$]
Financial Metrics affecting the MLTX estimates:
- Negative: Non-GAAP EPS, $ of -0.76 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -1.60 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term MLTX quotes
Long-term MLTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $4.57MM | $65.06MM | $54.12MM |
| Operating Income | $-4.57MM | $-65.06MM | $-54.12MM |
| Non-Operating Income | $0.03MM | $0.59MM | $10.14MM |
| R&D Expense | $35.52MM | $42.05MM | $31.80MM |
| Income(Loss) | $-4.54MM | $-64.47MM | $-43.98MM |
| Taxes | $0.00MM | $0.04MM | $0.09MM |
| Profit(Loss) | $-4.54MM | $-64.51MM | $-44.08MM |
| Stockholders Equity | $-11.65MM | $48.90MM | $495.68MM |
| Inventory | $1.32MM | $0.00MM | $0.00MM |
| Assets | $9.68MM | $76.84MM | $526.54MM |
| Operating Cash Flow | $-0.61MM | $-55.89MM | $-42.78MM |
| Capital expenditure | $0.05MM | $0.02MM | $0.28MM |
| Investing Cash Flow | $0.00MM | $-32.34MM | $-25.18MM |
| Financing Cash Flow | $-0.06MM | $119.69MM | $479.70MM |
| Earnings Per Share* | $-6.84 | $-2.20 | $-0.73 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.